Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: A randomized prospective clinical trial

被引:101
作者
Moore, M
Burak, WE
Nelson, E
Kearney, T
Simmons, R
Mayers, L
Spotnitz, WD
机构
[1] Univ Virginia, Dept Surg, Charlottesville, VA USA
[2] Univ Virginia, Tissue Adhes Ctr, Charlottesville, VA USA
[3] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA
[4] Univ Utah, Dept Surg, Salt Lake City, UT USA
[5] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Piscataway, NJ 08854 USA
[6] Strang Canc Prevent Ctr, Dept Surg, New York, NY USA
[7] Temple Univ, Dept Surg, Philadelphia, PA USA
关键词
D O I
10.1016/S1072-7515(01)00827-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Patients who have axillary dissections during lumpectomy or modified radical mastectomy for breast carcinoma accumulate serosanguinous fluid, potentially resulting in a seroma. Currently accepted practice includes insertion of one or more drains for fluid evacuation. This multicenter, randomized, controlled, phase II study was undertaken to evaluate whether a virally inactivated, investigational fibrin sealant is safe and effective when used as a sealing agent to reduce the duration and volume of serosanguinous fluid drainage and to determine the dose response: of this effect. STUDY DESIGN: Patients undergoing lumpectomy or modified radical mastectomy were randomized to treatment with 4, 8, or 16mL of fibrin sealant or control (no agent) at the axillary dissections site. Patients undergoing modified radical mastectomy also received an additional 4 or 8 mt of fibrin sealant at the skin flap site. Efficacy was evaluated by the number of days required for wound drainage and the volume of fluid drainage compared with control. Safety was confirmed by clinical course, the absence of viral seroconversion, and no major complications attributable co the sealant. RESULTS: The 4-mL axillary dissection dose of fibrin sealant significantly reduced the duration and quantity of fluid drainage from the axilla following lumpectomy (p less than or equal to 0.05). In the modified radical mastectomy patients, a 16-mL axillary dissection dose combined with an 8-mL skin flap dose was significantly effective in reducing the number of days to drain removal (p less than or equal to 0.05) and fluid drainage (p less than or equal to 0.01). There were no fibrin sealant patient viral seroconversions and no major complications attributable to the sealant. A number of wound infections were noted, although this may represent a center-specific effect. CONCLUSIONS: Application of fibrin sealant following axillary dissection at the time of lumpectomy or modified radical mastectomy can significantly decrease the duration and quantity of serosanguinous drainage. The viral safety of the product was also supported. (J Am Coll Surg 2001;192: 591-599. (C) 2001 by the American College of Surgeons).
引用
收藏
页码:591 / 599
页数:9
相关论文
共 37 条
[1]  
AITKEN DR, 1984, SURG GYNECOL OBSTET, V158, P327
[2]  
[Anonymous], 1994, CANC FACTS FIG
[3]   FIBRIN GLUE [J].
BRENNAN, M .
BLOOD REVIEWS, 1991, 5 (04) :240-244
[4]   SURGICAL MORBIDITY AFTER MASTECTOMY OPERATIONS [J].
BUDD, DC ;
COCHRAN, RC ;
STURTZ, DL ;
FOUTY, WJ .
AMERICAN JOURNAL OF SURGERY, 1978, 135 (02) :218-220
[5]  
Burak WE, 1997, J SURG ONCOL, V64, P27, DOI 10.1002/(SICI)1096-9098(199701)64:1<27::AID-JSO6>3.3.CO
[6]  
2-9
[7]   VIRUCIDAL SHORT-WAVELENGTH ULTRAVIOLET-LIGHT TREATMENT OF PLASMA AND FACTOR-VIII CONCENTRATE - PROTECTION OF PROTEINS BY ANTIOXIDANTS [J].
CHIN, S ;
WILLIAMS, B ;
GOTTLIEB, P ;
MARGOLISNUNNO, H ;
BENHUR, E ;
HAMMAN, J ;
JIN, RY ;
DUBOVI, E ;
HOROWITZ, B .
BLOOD, 1995, 86 (11) :4331-4336
[8]  
COONS MS, 1993, AM SURGEON, V59, P215
[9]   Wound infections after mastectomy or lumpectomy for breast cancer [J].
deFeiter, PW ;
Stockmann, HBAC ;
Wereldsma, JCJ ;
vanPutten, WLJ ;
vanAssendelft, PJ .
BREAST, 1997, 6 (01) :6-11
[10]  
Dinsmore RC, 2000, AM SURGEON, V66, P982